Asherman's syndrome epidemiology and demographics

Revision as of 19:38, 27 June 2022 by Saud Khan (talk | contribs)
Jump to navigation Jump to search

Asherman's syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Asherman's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Asherman's syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Asherman's syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Asherman's syndrome epidemiology and demographics

CDC on Asherman's syndrome epidemiology and demographics

Asherman's syndrome epidemiology and demographics in the news

Blogs on Asherman's syndrome epidemiology and demographics

Directions to Hospitals Treating Asherman's syndrome

Risk calculators and risk factors for Asherman's syndrome epidemiology and demographics

Editor(s)-in-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Canan S Fornusek, Ph.D.; Associate Editor-In-Chief: Saud Khan M.D.

Overview


Epidemiology and Demographics

The true prevalence of Asherman’s syndrome is unclear. The condition is estimated to affect 1.5% of women undergoing HSG [1], between 5 and 39% of women with recurrent miscarriage [2][3][4] and up to 40% of patients who have undergone D&C for retained products of conception [5]. It may occur in up to 13% of women undergoing a termination of pregnancy during the first trimester, and 30% in women undergoing a dilation and curettage (D and C) after a late spontaneous abortion.

Women with placental abnormalities (e.g., placenta increta) may have a higher risk of developing Asherman syndrome as the placenta adheres to deeper layers within the uterus and becomes more difficult to remove. The incidence may be as high as 23.4% in patients undergoing procedures two to four weeks after the initial procedure for a vaginal delivery or missed abortion. The risk increases for patients undergoing repeated procedures for bleeding or repeated elective termination of pregnancies.

It is found in 1.5% of women evaluated with a hysterosalpingogram (HSG) for infertility, between 5 and 39% of women with recurrent miscarriage. Asherman’s Syndrome may occur in 31% of women after the initial hysteroscopic resection of leiomyoma, and up to 46% after the second hysteroscopic resection.[6][7]

References

  1. Dmowski WP, Greenblatt RB. (1969). "Asherman's syndrome and risk of placenta accreta". Obstet Gynecol. 34 (2): 288–299. PMID 5816312.
  2. Rabau E, David A. (1963). "Intrauterine adhesions:etiology, prevention, and treatment". Obstet Gynecol. 22: 626–629. PMID 14082285.
  3. Toaff R. (1966). "Some remarks on posttraumatic uterine adhesions.in French". Rev Fr Gynecol Obstet. 61 (7): 550–552. PMID 5940506.
  4. Ventolini G, Zhang M, Gruber J. (2004). "Hysteroscopy in the evaluation of patients with recurrent pregnancy loss: a cohort study in a primary care population". Surg Endosc. 18 (12): 1782–1784. doi:10.1007/s00464-003-8258-y. PMID 15809790.
  5. Westendorp ICD, Ankum WM, Mol BWJ, Vonk J. (1998). "Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion". Hum Reprod. 13 (12): 3347–3350. doi:10.1093/humrep/13.12.3347. PMID 9886512.
  6. Chikazawa K, Imai K, Liangcheng W, Sasaki S, Horiuchi I, Kuwata T; et al. (2018). "Detection of Asherman's syndrome after conservative management of placenta accreta: a case report". J Med Case Rep. 12 (1): 344. doi:10.1186/s13256-018-1869-7. PMC 6245912. PMID 30454053.
  7. Tchente NC, Brichant G, Nisolle M (2018) [Asherman's syndrome : management after curettage following a postnatal placental retention and literature review.] Rev Med Liege 73 (10):508-512. PMID: 30335256


Template:WikiDoc Sources